1.
Clin Cancer Res
; 28(4): 609-610, 2022 02 15.
Article
in English
| MEDLINE | ID: covidwho-1685768
Subject(s)
Biomedical Research/methods , COVID-19/prevention & control , Neoplasms/therapy , Patient Care/methods , Research Report , American Cancer Society/organization & administration , Biomedical Research/statistics & numerical data , Biomedical Research/trends , COVID-19/epidemiology , COVID-19/virology , Humans , Medical Oncology/methods , Medical Oncology/statistics & numerical data , Medical Oncology/trends , Neoplasms/diagnosis , Pandemics/prevention & control , Patient Care/statistics & numerical data , Patient Care/trends , SARS-CoV-2/physiology , United States
2.
Cancer Discov
; 11(2): 233-236, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-1140381
ABSTRACT
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.